Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后症状、体征、
功能的
。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后症状、体征、
功能的
。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
纤维
不仅造成慢性
炎、
功能异常和影响愈后,而且是诸
慢性
病向
硬
发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬
的慢性丙
(CHC)
受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能变
。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维成
性肝炎、肝功能异常和影响愈后,而且是诸
性肝病向肝硬
发展
必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦代表本软件
观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能影响愈后,而且是诸
慢性肝病向肝硬化
必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿
死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若
现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤,比较
前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣时存在肝功能
和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维不仅造成慢性肝炎、肝功能异
响愈后,而且是诸
慢性肝病向肝硬
的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿
死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
纤维化不仅造成
炎、
功能异常和影响愈后,而
病向
硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的
丙
(CHC)患者接受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后症状、体征、
功能的变
。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
维
不仅造成慢性
炎、
功能异常和影响愈后,而且是诸
慢性
病向
硬
发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬
的慢性丙
(CHC)
接受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功和影响愈后,而且是诸
慢性肝病向肝硬化发
经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功
失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。